Sickle Cell Disease
ICER will assess the comparative clinical effectiveness and value of treatments for sickle cell disease:
- Crizanlizumab (Novartis) is a P-selectin inhibitor, is currently under FDA priority review with an anticipated decision expected in the first half of 2020.
- Voxelotor (Global Blood Therapeutics) is an HbS polymerization inhibitor, and Global Blood Therapeutics is planning to initiate and complete a rolling NDA for voxelotor before the end of 2019.
Date of review: March 2020
For questions, please contact Catherine Koola, Program Manager, at email@example.com.
The New England CEPAC will convene to deliberate and vote on evidence presented in ICER's report on treatments for sickle cell disease.